HIV / AIDS

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.

The adoption of numerous HIV prevention measures was associated with an 80% drop in the number of HIV diagnoses, a study evaluating the success of 56 Dean Street in London found.

Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.

The significance of treating HIV with single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide based on data demonstrated by the EMERALD and AMBER clinical trials.

The relationship between diabetes and obesity and therapies commonly used to manage patients with HIV infections.

What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

Strategies to help counsel and support newly diagnosed patients with HIV.

Criteria used to help establish and reach treatment goals for patients on antiretroviral therapy for HIV.

HIV risk perception and concern regarding HIV infection declined during the study.

A review of selected investigational long-active treatment options for HIV.

Long acting injectable PrEP therapies that are safe and effective are needed to increase options for at-risk individuals.

Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.

PrEP initiations, discontinuations and lapses all increased among Latinx patients post shelter-in-place orders.

A new study sought to approach the HIV epidemic in the United States through a distributional cost-effectiveness analysis across 6 cities.

Todd Brown, MD, PhD, of The Johns Hopkins University School of Medicine, recommends best practices for monitoring and managing patients with HIV for comorbid conditions.

A discussion regarding the benefits of training primary care physicians, nurse practitioners, and physician assistants on strategies to help manage patients with HIV infections.

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.

Some patients who switched appear to have done so in anticipation of clinical indications.

Recommendations for primary care physicians to help properly identify patients who should be tested for HIV, and an overview of available screening tests.

John Koethe, MD, of Vanderbilt University Medical Center, reacts to current trends in new HIV diagnoses among various patient populations.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.